InvestorsHub Logo
Followers 44
Posts 13348
Boards Moderated 0
Alias Born 02/27/2005

Re: None

Friday, 09/25/2020 9:35:54 PM

Friday, September 25, 2020 9:35:54 PM

Post# of 232275
i would be more concerned that nader has made definite deals to move the 13 batches of leronlimab in vials he has ordered for 2020 from samsung market value several $bilion imo assuming a batch equals 100,000 vials.so far nadar has paid samsung $30 million with a balance due $86 million.imo
data below courtesy of trding

The Company estimates that initial ramp-up costs to manufacture commercial grade leronlimab at scale could total approximately $116 million, with approximately $69 million payable over the course of calendar 2020, of which $30 million has been paid as of the date of this filing, and approximately $23 million payable during calendar 2021, and approximately $24 million payable in January of 2022.


On June 10, 2020 and July 27, 2020, the Company entered into Amendment #1 and Amendment #2, respectively, to the Samsung Agreement to increase the purchase order quantity of total drug substance batches to be produced during calendar year 2020 by seven batches for a total of 13 batches. Two batches have already been manufactured as of May 31, 2020. The incremental seven batches to be manufactured during calendar year 2020 will be reduced against the number of forecasted batches the Company planned to have manufactured during calendar year 2021. As part of this arrangement Samsung has allowed for the deferral of payments of certain costs to calendar years 2020, 2021 and 2022. These amendments increase the approximate contract commitment to approximately $103 million from approximately $60 million.















Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News